Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ciba-Geigy's Q-Vel

Executive Summary

Company submitted safety analysis to FDA April 19 for nocturnal leg muscle cramp product in support of Category I status for quinine sulfate. The report, by Richard Aster, MD, Medical College of Wisconsin, reviewed effect of quinine on thrombocytopenia and concluded: "quinine used at recommended dosage appears to be an exceedingly safe medication." The agency is also evaluating final efficacy data submitted Feb. 28. At FDA's request, Ciba-Geigy recently submitted raw data from the efficacy study for further statistical analysis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS015537

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel